STOK Similar Chart Price Prediction
The price of STOK is predicted to go up -6.71%, based on the high correlation periods with VRA. The similarity of these two price pattern on the periods is 95.48%.
STOK
VRA
Down: -6.71%Similarity: 95.48%
STOK Revenue Forecast
STOK EPS Forecast
STOK FAQs
What is bull’s view on STOK?
What is bear's view on STOK?
What is STOK revenue forecast for next quarter？
What is STOK eps forecast for next quarter？
STOK Analyst's Forecast
Rudy Li
Chardan Capital
Strong Buy
2024-12-20
Price Target
$24
Upside
+105.48%
Chardan initiated coverage of Stoke Therapeutics with a Buy rating and $24 price target. The firm cites the potential of the company's lead asset zorevunersen for the treatment of Dravet syndrome for the Buy rating. It believes STK-001 has demonstrated solid proof-of-concept with "robust" treatment effect and favorable safety in the Phase 1/2 studies. STK-001 could become the first disease modifying therapy approved for this rare epilepsy disease, for which Chardan models over $1B in peak sales, the analyst tells investors in a research note.
